Response to comment. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?

We thank Drs. Deane and Horowitz (1) for bringing this work to our attention. Their results provide further support for our contention that glucagon-like peptide 1 (GLP-1) therapy represents a safe and effective intervention to improve glycemic control in critically ill, hospitalized patients both with and without preexisting type 2 diabetes. In agreement with us (2), they recognize that “insulin has substantial limitations, particularly as excess dosing precipitates hypoglycemia” (1), and a number of recent trials have failed to demonstrate any benefit in morbidity or mortality in critically ill hospitalized patients who receive intensive insulin therapy (3–5).